Infectious Disease Approved Deal Benchmarks — Ex-US

Understanding Infectious Disease Deal Benchmarks at Approved

Approved Infectious Disease licensing deals in Ex-US territory command a median upfront payment of $1.6B, with values ranging from $1.3B at the low end to $2.1B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the infectious disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $2.8B to $3.6B, with a median of $3.2B. Royalty rates for infectious disease assets at this stage typically fall between 12.3% and 21.9% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.